Trial Profile
A Randomized Double-blind Placebo-controlled Parallel Group Study Evaluating Paliperidone Palmitate in the Prevention of Recurrence in Patients With Schizophrenia. Placebo Consists of 20% Intralipid (200 mg/mL) Injectable Emulsion
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Jul 2018
Price :
$35
*
At a glance
- Drugs Paliperidone (Primary)
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Sponsors Janssen Research & Development
- 19 Jun 2018 Results (n=352) of post-hoc analysis published in the Journal of Clinical Psychiatry
- 18 Jul 2016 Result of post-hoc analysis of this and one other phase III trial published in the International Clinical Psychopharmacology (2016).
- 01 Feb 2010 Primary endpoint results published in Schizophrenia Research